NCI’s Natural History Study of COVID-19 in Cancer

Remembering Valerie Guild, a Tireless Advocate for Patients with Melanoma
May 29, 2020
Doctor patient CT scan
Now Enrolling: FEATURE (EA1183) – FDG PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer
May 29, 2020

NCI’s Natural History Study of COVID-19 in Cancer

This month, the National Cancer Institute (NCI) launched a large clinical cohort study of people with cancer who have COVID-19. The NCI COVID-19 in Cancer Patients Study (NCCAPS) will involve all of the NCI’s clinical trial programs (those are the National Clinical Trials Network, NCI Community Oncology Research Program, and Experimental Ttherapeutics Clinical Trials Network) and NCI-designated Cancer Centers. Sites that participate in NCCAPS can expect full reimbursement for each patient enrolled.

The purpose of the trial is to better understand the virus’s effect on people with cancer. NCCAPS is currently open to adults who are undergoing testing for SARS-CoV-2 or already have COVID-19 and are receiving cancer treatment at a health care facility. The trial will expand to include children with cancer and COVID-19 at a later date.

NCCAPS is collecting documentation from more than 2,000 patients across over 1,000 sites, and following those patients for an extended period. Eligibility criteria includes:

Step 0

  • Age ≥≥ 18 years old
  • Patient must have a prior or current cancer diagnosis (e.g. solid tumor or hematologic malignancy)
  • HIV-infected patients are eligible
  • Patients with brain metastases are eligible
  • Co-enrollment on other clinical trials (for cancer or for COVID-19) is allowed

Step 1

  • Positive SARS CoV-2 test within the 14 days prior to enrollment to Step 1

Please consider participating in this important effort that will help guide future treatment for cancer patients who develop COVID-19. Sign up with the NCI to receive updates about NCCAPS and learn more at www.CTSU.org.

Leave a Reply

Your email address will not be published.